Cargando…
Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
OBJECTIVES: Elevated concentrations of soluble urokinase plasminogen activator receptor (suPAR) predict progression to severe respiratory failure (SRF) or death among patients with COVID-19 pneumonia and guide early anakinra treatment. As suPAR testing may not be routinely available in every health-...
Ejemplares similares
-
Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial
por: Akinosoglou, Karolina, et al.
Publicado: (2022) -
Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
por: Kyriazopoulou, Evdoxia, et al.
Publicado: (2021) -
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
por: Kyriazopoulou, Evdoxia, et al.
Publicado: (2021) -
Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure
por: Giamarellos-Bourboulis, Evangelos J., et al.
Publicado: (2022) -
Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19
por: Kassianidis, Georgios, et al.
Publicado: (2022)